Cowen & Co. analyst Marc Frahm reiterated a Buy rating on Adaptimmune Therapeutics (ADAP) today. The company’s shares opened today at $4.89, close to its 52-week low of $3.55.
According to TipRanks.com, Frahm is a 3-star analyst with an average return of 5.3% and a 65.6% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Odonate Therapeutics Llc, Unum Therapeutics Inc, and Blueprint Medicines.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adaptimmune Therapeutics.
See today’s analyst top recommended stocks >>
Based on Adaptimmune Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $35.87 million. In comparison, last year the company had a GAAP net loss of $21.22 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors.
